Identification of target epitopes of SARS-CoV-2 neutralizing antibody | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Start & end year
2021
2024
Known Financial Commitments (USD)
$36,270
Funder
KAKENHI
Principal Investigator
Hokko Natsuko Unspecified
Research Location
Japan
Lead Research Institution
Osaka Municipal University
Research Priority Alignment
N/A

Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Not Applicable
Vulnerable Population
Not applicable
Occupations of Interest
Not applicable

Abstract

2 Publications linked via Europe PMC

Last Updated:4 days ago

View all publications at Europe PMC

Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.

Authors
Nakagama Y, Candray K, Kaku N, Komase Y, Rodriguez-Funes MV, Dominguez R, Tsuchida T, Kunishima H, Nagai E, Adachi E, Ngoyi DM, Yamasue M, Komiya K, Hiramatsu K, Uemura N, Sugiura Y, Yasugi M, Yamagishi Y, Mikamo H, Shiraishi S, Izumo T, Nakagama S, Watanabe C, Nitahara Y, Tshibangu-Kabamba E, Kakeya H, Kido Y.
Publish Year
2023
Journal
The Journal of infectious diseases
DOI
10.1093/infdis/jiac492

View at Europe PMC

Cumulative seroprevalence among healthcare workers after the first wave of the COVID-19 pandemic in El Salvador, Central America.